CD146, an epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 4, 2012, Pages 1127-1132

  Zeng, Qiqun ^a   Li, Weidong ^b   Lu, Di ^a   Wu, Zhenzhen ^a   Duan, Hongxia ^a   Luo, Yongting ^a   Feng, Jing ^a   Yang, Dongling ^a   Fu, Li ^b   Yan, Xiyun ^a  

^a INSTITUTE OF BIOPHYSICS   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; F actin

Indexed keywords

CD146 ANTIGEN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TRANSCRIPTION FACTOR SLUG; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CANCER INVASION; CANCER PROGNOSIS; CANCER STEM CELL; CELL DIFFERENTIATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION;

ADULT; ANIMALS; ANTIGENS, CD146; BREAST NEOPLASMS; CELL LINE; DOGS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, SCID; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHOA GTP-BINDING PROTEIN; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 84863012785     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1111053108     Document Type: Article

References (29)

1. Jemal A, et al. (2011) Global cancer statistics. CA Cancer J Clin 61:69-90.
2. Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139:871-890.
3. Mani SA, et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704-715. (Pubitemid 351636299)
4. Kang Y, Massagué J (2004) Epithelial-mesenchymal transitions: Twist in development and metastasis. Cell 118:277-279. (Pubitemid 39061108)
5. Yilmaz M, Christofori G (2009) EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 28:15-33.
6. Mostert B, Sleijfer S, Foekens JA, Gratama JW (2009) Circulating tumor cells (CTCs): Detection methods and their clinical relevance in breast cancer. Cancer Treat Rev 35:463-474.
7. Lehmann JM, Riethmüller G, Johnson JP (1989) MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci USA 86:9891-9895. (Pubitemid 20030740)
8. Yan X, et al. (2003) A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth. Blood 102:184-191. (Pubitemid 36759653)
9. Bu P, et al. (2006) Anti-CD146 monoclonal antibody AA98 inhibits angiogenesis via suppression of nuclear factor-kappaB activation. Mol Cancer Ther 5:2872-2878. (Pubitemid 44849014)
10. Kang Y, et al. (2006) Knockdown of CD146 reduces the migration and proliferation of human endothelial cells. Cell Res 16:313-318.
11. Zheng C, et al. (2009) Endothelial CD146 is required for in vitro tumor-induced angiogenesis: The role of a disulfide bond in signaling and dimerization. Int J Biochem Cell Biol 41:2163-2172.
12. Liu Q, et al. (2004) Pre-eclampsia is associated with the failure of melanoma cell adhesion molecule (MCAM/CD146) expression by intermediate trophoblast. Lab Invest 84:221-228. (Pubitemid 41656503)
13. Liu Q, et al. (2008) Blockade of adhesion molecule CD146 causes pregnancy failure in mice. J Cell Physiol 215:621-626. (Pubitemid 351632683)
14. Wu GJ, et al. (2001) Isolation and characterization of the major form of human MUC18 cDNA gene and correlation of MUC18 over-expression in prostate cancer cell lines and tissues with malignant progression. Gene 279:17-31.
15. Aldovini D, et al. (2006) M-CAM expression as marker of poor prognosis in epithelial ovarian cancer. Int J Cancer 119:1920-1926. (Pubitemid 44356852)
16. Zabouo G, et al. (2009) CD146 expression is associated with a poor prognosis in human breast tumors andwith enhanced motility in breast cancer cell lines. Breast Cancer Res 11:R1.
17. Ridley AJ (2001) Rho GTPases and cell migration. J Cell Sci 114:2713-2722.
18. Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G (1998) A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 392:190-193. (Pubitemid 28162793)
19. Finn RS, et al. (2007) Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat 105:319-326. (Pubitemid 47596452)
20. Bhowmick NA, et al. (2001) Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell 12:27-36. (Pubitemid 32060576)
21. Gulhati P, et al. (2011) mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res 71:3246-3256.
22. Martín-Villar E, et al. (2006) Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition. J Cell Sci 119:4541-4553. (Pubitemid 44830653)
23. Alves CC, Carneiro F, Hoefler H, Becker KF (2009) Role of the epithelial-mesenchymal transition regulator Slug in primary human cancers. Front Biosci 14:3035-3050.
24. Leong KG, et al. (2007) Jagged1-mediated Notch activation induces epithelial-tomesenchymal transition through Slug-induced repression of E-cadherin. J Exp Med 204:2935-2948. (Pubitemid 350179562)
25. Luo Y, et al. (2011) Recognition of CD146 as an ERM-binding protein offers novel mechanisms for melanoma cell migration. Oncogene, 10.1038/onc.2011.244.
26. Anders CK, Carey LA (2009) Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer 9(Suppl 2):S73-S81.
27. Bidlingmaier S, et al. (2009) Identification of MCAM/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma. Cancer Res 69:1570-1577.
28. Sato A, et al. (2010) Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium. Mod Pathol 23:1458-1466.
29. Wu GJ, et al. (2001) Expression of a human cell adhesion molecule, MUC18, in prostate cancer cell lines and tissues. Prostate 48:305-315.